Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.

ABSTRACT:

Background

Cancer immunotherapy (CIT) often triggers immune-related adverse events (irAEs). Analysis of irAEs in large checkpoint inhibitor (CPI) trials has enhanced their management and demonstrated their prognostic value for treatment outcome. However, data on irAEs in non-standard CITs are limited, and systematic exploration is lacking. Identifying predictive biomarkers for irAEs in these therapies is still emerging and essential for improving patient care.

Methods

We established a harmonized data mart from 27 early-phase CIT trials, encompassing 14 molecules with diverse mechanisms across various cancer indications. This dataset includes 3,608 patients, both CPI-naïve and CPI-experienced, with detailed information on clinical data, tumor characteristics, soluble biomarke

SUBMITTER: Lamparter DF 

PROVIDER: S-EPMC12625878 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature